CRDF
Cardiff Oncology Inc

18,815
Mkt Cap
$99.69M
Volume
409,494.00
52W High
$4.99
52W Low
$1.48
PE Ratio
-1.86
CRDF Fundamentals
Price
$1.60
Prev Close
$1.48
Open
$1.52
50D MA
$2.49
Beta
1.47
Avg. Volume
1.84M
EPS (Annual)
-$0.9539
P/B
2.04
Rev/Employee
$20,696.97
Loading...
Loading...
News
all
press releases
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
FY2027 Earnings Estimate for CRDF Issued By Zacks Small Cap
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at Zacks Small Cap lifted their FY2027 earnings estimates for Cardiff Oncology in a report issued on Tuesday, February...
MarketBeat·1d ago
News Placeholder
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF)
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors bought 2,705 call options on the company. This represents an...
MarketBeat·10d ago
News Placeholder
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study
Cardiff Oncology (NASDAQ:CRDF) outlined a management transition and provided an updated clinical data readout for onvansertib during a company conference call focused on its ongoing Phase II CRDF-004...
MarketBeat·10d ago
News Placeholder
Q4 Earnings Estimate for CRDF Issued By Noble Financial
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Analysts at Noble Financial issued their Q4 2025 earnings per share estimates for Cardiff Oncology in a research report issued to clients and...
MarketBeat·1mo ago
News Placeholder
Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF)
Noble Financial started coverage on Cardiff Oncology in a research report on Monday. They issued an "outperform" rating and a $12.00 price objective for the company...
MarketBeat·1mo ago
News Placeholder
Stock Traders Purchase High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF)
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the target of unusually large options trading on Tuesday. Traders purchased 2,314 call options on the stock. This represents an increase of...
MarketBeat·2mo ago
News Placeholder
Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF
Flputnam Investment Management Co. lifted its position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 1,008.8% during the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·2mo ago
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Hold" by Brokerages
Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been given an average recommendation of "Hold" by the five analysts that are currently covering the firm, MarketBeat reports. One...
MarketBeat·2mo ago
News Placeholder
FY2025 Earnings Forecast for CRDF Issued By Zacks Small Cap
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Zacks Small Cap issued their FY2025 earnings per share (EPS) estimates for shares of Cardiff Oncology in a report issued on Tuesday, December 9th...
MarketBeat·2mo ago
<
1
2
...
>

Latest CRDF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.